DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.
Cinrebafusp alfa, a HER2/4-1BB bispecific antibody, demonstrates manageable safety and encouraging anti-tumor activity in patients with HER2-expressing solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.